Correlation between N-Acetyltransferase 2 (NAT2) Polymorphism Genotype with Plasma Isoniazid (INH) Concentration in MDR TB Patients Receiving Short Regimen in West Sumatera
DOI:
https://doi.org/10.36497/jri.v42i1.283Keywords:
NAT2, INH, polymorphism, MDR-TBAbstract
Background: Isoniazid (INH) is one of the most potent TB drug. High dose INH is used in short regimen MDR TB drugs. The genetic polymorphism of NAT2 affects the acetylation status. Awareness of the patients’ acetylator status is important to determine the risk of toxicity, treatment failure and drug resistance. The aim of this study was to demonstrate NAT2 genotype association with INH plasma concentration after 2 hours of oral INH therapy.
Methods: This was a cross sectional study of MDR TB patients who received short term combination therapy at RSUP Dr. M.Djamil Padang, Achmad Muchtar Hospital Bukittinggiand West Sumatra Pulmonary Hospital from September 2019 to February 2020. Patients were examined for NAT2 genotype and plasma INH concentration. The results of the plasma INH concentrations obtained were evaluated based on the NAT2 acetylator phenotype group.
Results: The majority of the subjects weremen (62.5%), aged 40-64 years (50%), had the most common comorbid of diabetes mellitus (31.25%), were normoweight (75%) and had negative HIV status (93.8%). A total of 7 alleles consisting of 7 SNPs and 7 variations of the NAT2 genotype were found in MDR TB patients who received short-term therapy. The NAT2*12A alleles (56.25%) was the most common allele and was a fast acetylator. Based on the bimodal distribution, the median concentration of INH in the fast and slow acetylator were 1.25 µg/ml and 5.24 µg/ml, respectively. The median values of INH concentration based on the trimodal distribution for fast, intermediate, and slow acetylators were 1.25 µg/ml, 2.17 µg/ml and 5.24 µg/ml.
Conclusion: There were no correlations between the type of NAT2 acetylator phenotype and plasma INH concentrations.
Downloads
References
World Health Organization. Global tuberculosis report 2018. World Health Organization. Geneva; 2018.
World Health Organization. Global tuberculosis report 2017. World Health Organization. Geneva; 2017.
World Health Organization. Global tuberculosis report 2016. World Health Organization. Geneva; 2016.
Kementerian Kesehatan Republik Indonesia. Petunjuk teknis pengobatan pasien TB resisten obat dengan paduan standar jangka pendek di fasyankes TB resisten obat. 2017.
World Health Organization. WHO Treatment Guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization. Geneva; 2018.
Klein DJ, Boukouvala S, McDonagh EM, Shuldiner SR, Laurieri N, Thorn CF, et al. PharmGKB summary: isoniazid pathway, pharmacokinetics. Pharmacogenet Genomics [Internet]. 2016;26(9):436–44. Available from: https://pubmed.ncbi.nlm.nih.gov/27232112
Singh N, Dubey S, Chinnaraj S, Golani A, Maitra A. Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients. Mol Diagn Ther. 2009;13(1):49–58.
Zabost A, Brzezińska S, Kozińska M, Błachnio M, Jagodziński J, Zwolska Z, et al. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients. Biomed Res Int. 2013;2013:853602.
Hemanth Kumar AK, Ramesh K, Kannan T, Sudha V, Haribabu H, Lavanya J, et al. N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis. Indian J Med Res. 2017;145(1):118–23.
Pradipta J, Soepandi PZ, Burhan E, Isbaniah F, Agustin H, Handayani D, et al. Adverse Reactions Among Patients Being Treated with Shorter Multi-Drug Resistant Tuberculosis Regimen at Persahabatan Hospital, Indonesia. Respirology. 2018;23:72–3.
Rychlik-Sych M, Skretkowicz J, Gawrońska-Szklarz B, Górnik W, Sysa-Jedrzejowska A, Skretkowicz-Szarmach K. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep. 2006;58(1):22–9.
Tanigawara Y, Kita T, Aoyama N, Gobara M, Komada F, Sakai T, et al. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull. 2002;25(8):1058–62.
The Arylamine N-Acetyltransferase Gene Nomenclature Committee. Supplementary Table 2: Distribution and annotation of NAT genes in sequenced genomes of protists (a) [Internet]. The Arylamine N-Acetyltransferase Gene Nomenclature Committee. 2016 [cited 2020 May 1]. Available from: http://nat.mbg.duth.gr/Human NAT2 alleles_2013.htm
Magalon H, Patin E, Austerlitz F, Hegay T, Aldashev A, Quintana-Murci L, et al. Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur J Hum Genet [Internet]. 2008;16(2):243–51. Available from: https://doi.org/10.1038/sj.ejhg.5201963
Yuliwulandari R, Sachrowardi Q, Nishida N, Takasu M, Batubara L, Susmiarsih TP, et al. Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. J Hum Genet. 2008;53(3):201–9.
Susilowati RW, Prayuni K, Razari I, Bahri S, Yuliwulandari R. High frequency of NAT2 slow acetylator alleles in the Malay population of Indonesia: an awareness to the anti-tuberculosis drug induced liver injury and cancer. Med J Indones [Internet]. 2017;26(1):7–13. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/1563
Patin E, Harmant C, Kidd KK, Kidd J, Froment A, Mehdi SQ, et al. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat. 2006;27(7):720.
Ensembl. Ensembl genome browser 105 [Internet]. Ensembl. 2020 [cited 2020 Apr 30]. Available from: http://asia.ensembl.org/index.html
Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One. 2011;6(4):e18507.
Pramono AA, Penggoam S, Sahiratmadja E, Utami NV, Achmad TH, Panigoro R. Status Asetilator Gen NAT2 pada Pasien Tuberkulosis dan Tuberkulosis dengan Diabetes Melitus di Kupang, Nusa Tenggara Timur. Maj Kedokt Bandung. 2017;49(1):61–6.
Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55(2):169–77.
Wang P, Pradhan K, Zhong X-B, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016;6(5):384–92.
Chen B, Li J-H, Xu Y-M, Wang J, Cao X-M. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients. Clin Chim Acta. 2006;365(1–2):104–8.
Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther. 1976;19(5 Pt 2):610–25
World Health Organization. Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis [Internet]. Geneva PP - Geneva: World Health Organization; 2018. Available from: https://apps.who.int/iris/handle/10665/260440
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
